INS and Hypoglycemia: A recent clinical trial to evaluate the effect of the combination of linagliptin and insulin on metabolic control and prognosis in hospitalized patients with COVID-19 and hyperglycemia revealed that the combination of treatments reduced the relative risk of assisted mechanical ventilation by 74% and improved better pre and postprandial glucose levels with lower insulin requirements, and no higher risk of hypoglycemia [146].